Top Markets
Coin of the day
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Kedudukan dalam Saham #32097
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Harga Saham
$0.21483059
Disegerakkan terakhir: 2024-05-07
Modal Pasaran
$11.13M
Perubahan (1 hari)
0.34%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan Antibe Therapeutics Inc. (ATE)

Kategori

Pendapatan untuk Antibe Therapeutics Inc. (ATE)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Antibe Therapeutics Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Antibe Therapeutics Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US